Brian Druker, M.D.
Director, OHSU Knight Cancer Institute
Associate Dean for Oncology, OHSU School of Medicine
JELD-WEN Chair of leukemia research
Dr. Druker joined OHSU in 1993 and became director of the OHSU Cancer Institute in 2007. In 2008, the institute was renamed the OHSU Knight Cancer Institute thanks to a transformational gift of $100 million from Phil and Penny Knight. Dr. Druker revolutionized the way cancer is treated by developing the drug Gleevec, which is designed to zero in on the specific cancer-causing molecules that cause chronic myeloid leukemia (CML), eliminating cancer cells while avoiding serious damage to other, non-cancerous cells. Gleevec, which attacks the protein causing overproduction of white blood cells in CML, is also used to treat gastrointestinal stromal tumors (GIST) and five other cancers.
Druker’s many achievements include being named a Howard Hughes Medical Investigator in 2002 and being elected to the Institute of Medicine of the National Academies in 2003, the American Association of Physicians in 2006, and the National Academy of Sciences in 2007. The soft-spoken Minnesotan, who fits exercise into his schedule by running to work, received his M.D. from the University of California School of Medicine at San Diego, completed his residency in internal medicine at Washington University in St. Louis, Missouri, and performed his oncology fellowship at Dana-Farber Cancer Institute at Harvard Medical School. He has been awarded the AACR-Richard and Hinda Rosenthal Award, the Warren Alpert Prize from Harvard Medical School, the American Society of Hematology’s Dameshek Prize, the Lance Armstrong Foundation’s Pioneer of Survivorship Carpe Diem Award, the American Cancer Society’s Medal of Honor, the Kettering Prize from General Motors Cancer Research Foundation, the David A. Karnofsky Award from the American Society of Clinical Oncology, the Robert-Koch Award, and the 2009 Lasker-DeBakey Award for Clinical Medical Research, among many others. Read more about Dr. Brian Druker.
OHSU Knight Cancer Institute leadership
- Tomasz Beer, M.D.
- Steve Stadum
Chief Operating Officer
- Kristin Bialobok, M.S.N.
Associate Director of Administration
- Ann Raish, M.H.A.
Vice President of Oncology Services
- Lisa Coussens, Ph.D.
Associate Director of Basic Research
- Joe Gray Ph.D.
Associate Director of Translational Research
- Christopher Amling, M.D., F.A.C.S.
Chief, Division of Urology
- Kevin Billingsley, M.D.
Chief, Division of Surgical Oncology
- Charles Thomas, M.D.
Chair, Department of Radiation Medicine
- Raymond Bergan, M.D.
Chief, Division of Hematology and Medical Oncology